Bluejay Diagnostics Financials
| BJDX Stock | USD 4.19 0.24 6.08% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.55 | 1.64 |
|
|
Investors should never underestimate Bluejay Diagnostics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Bluejay Diagnostics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Bluejay Diagnostics.
Net Income |
|
Bluejay | Select Account or Indicator |
Understanding current and past Bluejay Diagnostics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bluejay Diagnostics' financial statements are interrelated, with each one affecting the others. For example, an increase in Bluejay Diagnostics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Bluejay Diagnostics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bluejay Diagnostics. Check Bluejay Diagnostics' Beneish M Score to see the likelihood of Bluejay Diagnostics' management manipulating its earnings.
Bluejay Diagnostics Stock Summary
Bluejay Diagnostics competes with Bone Biologics, Nuwellis, Heart Test, Tivic Health, and Nexalin Technology. Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts. Bluejay Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.Specialization | Health Care, Health Care Equipment & Services |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US0956331039 |
| CUSIP | 095633103 095633400 095633301 095633509 |
| Location | Massachusetts; U.S.A |
| Business Address | 360 Massachusetts Avenue, |
| Sector | Health Care Equipment & Supplies |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | bluejaydx.com |
| Phone | 844 327 7078 |
| Currency | USD - US Dollar |
Bluejay Diagnostics Key Financial Ratios
| Return On Equity | -1.39 | ||||
| Price To Sales | 54.99 X | ||||
| Gross Profit | 48.91 K | ||||
| EBITDA | (9.17 M) | ||||
| Net Income | (9.95 M) |
Bluejay Diagnostics Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 1.5M | 21.0M | 13.5M | 4.9M | 5.6M | 9.2M | |
| Other Current Liab | 414.6K | 341.4K | 835.7K | 1.1M | 1.3M | 1.3M | |
| Net Debt | 143.6K | (19.0M) | (9.6M) | (1.9M) | (1.7M) | (1.8M) | |
| Retained Earnings | (4.2M) | (7.7M) | (17.0M) | (27.0M) | (24.3M) | (23.0M) | |
| Accounts Payable | 374.9K | 295.8K | 635.8K | 491.5K | 565.2K | 402.0K | |
| Cash | 912.4K | 19.0M | 10.1M | 2.2M | 2.5M | 2.4M | |
| Other Current Assets | 61.1K | 1.6M | 1.7M | 1.0M | 1.2M | 974.5K | |
| Total Liab | 5.7M | 637.2K | 2.0M | 2.0M | 1.8M | 2.3M | |
| Net Invested Capital | (3.2M) | 20.4M | 11.5M | 2.9M | 3.3M | 6.6M | |
| Total Current Assets | 1.1M | 20.7M | 11.8M | 3.2M | 3.7M | 3.5M | |
| Net Working Capital | (787.2K) | 20.0M | 10.1M | 1.4M | 1.7M | 1.6M |
Bluejay Diagnostics Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Net Interest Income | (27.0K) | (367.5K) | (97.9K) | 164.9K | 189.6K | 199.1K | |
| Gross Profit | (157.0K) | (145.7K) | 48.9K | (781.0K) | (702.9K) | (667.7K) | |
| Operating Income | (1.2M) | (3.2M) | (9.3M) | (10.3M) | (9.3M) | (8.8M) | |
| Ebit | (1.2M) | (3.2M) | (9.3M) | (10.0M) | (9.0M) | (8.5M) | |
| Research Development | 527.3K | 1.1M | 4.2M | 5.7M | 6.6M | 6.9M | |
| Ebitda | (1.0M) | (3.1M) | (9.0M) | (9.2M) | (8.3M) | (7.8M) | |
| Cost Of Revenue | 157.0K | 145.7K | 200.1K | 781.0K | 898.1K | 943.0K | |
| Income Before Tax | (1.2M) | (3.5M) | (9.3M) | (10.0M) | (9.0M) | (8.5M) | |
| Net Income | (1.1M) | (3.7M) | (9.2M) | (10.0M) | (9.0M) | (8.5M) | |
| Income Tax Expense | (32.6K) | 241.4K | (69.1K) | 5.0 | 5.75 | 5.46 |
Bluejay Diagnostics Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Bluejay Diagnostics. It measures of how well Bluejay is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Bluejay Diagnostics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Bluejay had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Bluejay Diagnostics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Investments | 1.9K | (23.9K) | (1.2M) | (854.5K) | (769.0K) | (730.6K) | |
| Change In Cash | 816.4K | 18.1M | (8.9M) | (7.9M) | (7.1M) | (6.8M) | |
| Free Cash Flow | (508.7K) | (4.4M) | (8.9M) | (9.0M) | (8.1M) | (7.7M) | |
| Depreciation | 157.0K | 145.7K | 306.4K | 781.0K | 898.1K | 943.0K | |
| Other Non Cash Items | (153.5K) | 222.0K | 237.4K | 3.1K | 3.6K | 3.7K | |
| Net Income | (1.2M) | (3.5M) | (9.3M) | (10.0M) | (9.0M) | (8.5M) | |
| End Period Cash Flow | 912.4K | 19.0M | 10.1M | 2.2M | 2.5M | 2.4M |
Bluejay Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bluejay Diagnostics's current stock value. Our valuation model uses many indicators to compare Bluejay Diagnostics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bluejay Diagnostics competition to find correlations between indicators driving Bluejay Diagnostics's intrinsic value. More Info.Bluejay Diagnostics is rated third in return on equity category among its peers. It is rated fifth in return on asset category among its peers . At this time, Bluejay Diagnostics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bluejay Diagnostics' earnings, one of the primary drivers of an investment's value.Bluejay Diagnostics Systematic Risk
Bluejay Diagnostics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Bluejay Diagnostics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Bluejay Diagnostics correlated with the market. If Beta is less than 0 Bluejay Diagnostics generally moves in the opposite direction as compared to the market. If Bluejay Diagnostics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bluejay Diagnostics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bluejay Diagnostics is generally in the same direction as the market. If Beta > 1 Bluejay Diagnostics moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Bluejay Diagnostics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Bluejay has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Bluejay Diagnostics' financials are consistent with your investment objective using the following steps:- Review Bluejay Diagnostics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Bluejay Diagnostics' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Bluejay Diagnostics' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Bluejay Diagnostics' stock is overvalued or undervalued.
Today, most investors in Bluejay Diagnostics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bluejay Diagnostics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Bluejay Diagnostics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Bluejay Diagnostics March 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Bluejay Diagnostics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bluejay Diagnostics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bluejay Diagnostics based on widely used predictive technical indicators. In general, we focus on analyzing Bluejay Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bluejay Diagnostics's daily price indicators and compare them against related drivers.
| Downside Deviation | 6.73 | |||
| Information Ratio | 0.0218 | |||
| Maximum Drawdown | 42.86 | |||
| Value At Risk | (12.22) | |||
| Potential Upside | 10.59 |
Additional Tools for Bluejay Stock Analysis
When running Bluejay Diagnostics' price analysis, check to measure Bluejay Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluejay Diagnostics is operating at the current time. Most of Bluejay Diagnostics' value examination focuses on studying past and present price action to predict the probability of Bluejay Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluejay Diagnostics' price. Additionally, you may evaluate how the addition of Bluejay Diagnostics to your portfolios can decrease your overall portfolio volatility.